Low-dose isotretinoin does not affect ovarian reserve
Isotretinoin, one of the most frequently used drugs in routine dermatological practice, has been raised for teratogenicity with a black box warning. The aim of the current study was to evaluate the effect of low-dose isotretinoin on ovarian reserve in women with moderate to severe acne. A 6-month prospective controlled cohort study of 60 female acne patients and 66 controls receiving low-dose isotretinoin. Effects on ovarian reserve were evaluated by anti-Müllerian hormone, ovarian volume, and antral follicle count.
As a result, there was no significant difference in serum anti-Mullerian hormone levels between isotretinoin-treated and control patients. In addition, there was no significant change in anti-Müllerian hormone levels before and after treatment in treated patients. Both ovarian volume and antral follicle number did not change significantly before and after treatment
Comments
Post a Comment